Surlorian not checked
RyCarma Therapeutics, Inc. · S48168 · ARM 210
FollowEvery change as it happens, and a Monday email
Trials
1 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Autosomal Dominant RYR1-Related Myopathy
- Main trialPhase 2
- “This study is testing a medicine called surlorian in adults who have a genetic muscle condition known as autosomal dominant RYR1-related myopathy (RYR1-RM). The goal is to find out whether surlorian improves muscle weakness, and whether it is safe and well tolerated.”In the company’s words, NCT07560020 on ClinicalTrials.gov
- Other names
- S48168 · ARM 210
Coming up1
- 27 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 27 Aug 2027 | A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy | |
| Phase 2Terminated | 1 Apr 2024 | Treatment of an Inherited Ventricular Arrhythmia | |
| Phase 1Completed | 30 Dec 2022 | S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026